Semi-Solid Dosage CDMO Market Size & Growth Forecast 2027–2036, By Segments (Route of Administration, End Use, Product, Service), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Semi-Solid Dosage CDMO Market size stood at USD 42.8 billion in 2026 and is predicted to grow at a 11.31% CAGR from 2027 to 2036, crossing USD 124.96 billion by 2036. The industry revenue for 2027 is calculated at USD 46.87 billion.
Get more details on this report
Request Free Sample ReportSemi-Solid Dosage CDMO Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 43.85% share due to established outsourcing base, strong regulatory systems, concentration of pharmaceutical developers, and advanced semi-solid formulation and scale-up expertise.
- Asia Pacific is expanding at 13.22% CAGR, driven by cost-competitive outsourcing, capacity buildout, flexible manufacturing demand, and strengthening technical capabilities of regional CDMOs and infrastructure.
Segment Momentum
- Topical accounted for 84.1% of the market in 2026, supported by widespread use of creams, gels, and ointments, mature formulation processes, scalable manufacturing, and consistent outsourcing demand from clients.
- Biopharmaceutical companies are growing fastest as they seek flexible outsourcing for complex semi-solid formulations, allowing product development to advance without significant in-house manufacturing investment.
Market Expansion Drivers
- Growing prevalence of skin disorders increasing outsourcing demand for topical formulation manufacturing.
- Rising pharmaceutical R&D investments accelerating development of complex semi-solid drug formulations.
- Strategic partnerships between pharma companies and CDMOs expanding specialized production capabilities.
Leading Market Participants
- Prominent players in the semi-solid dosage CDMO market include Piramal Pharma Solutions (India), Bora Pharmaceuticals Co., Ltd. (Taiwan), Cambrex Corporation (United States), Pierre Fabre Group (France), Ascendia Pharmaceuticals, Inc. (United States), DPT Laboratories, Ltd. (United States), LGM Pharma, LLC (United States), Pace Analytical Life Sciences, LLC (United States), Catalent, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 42.8 billion
- 2027 Estimated Market Size: USD 46.87 billion.
- Projected Market Size: USD 124.96 billion by 2036
- Growth Forecast: 11.31% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Topical (Route of Administration) | Pharmaceutical Companies (End Use) | Creams and Lotions (Product) | Contract Manufacturing (Service)
- Emerging Opportunity Segment: Transdermal (Route of Administration) | Biopharmaceutical Companies (End Use) | Ointments (Product) | Contract Development (Service)
Market Growth Drivers and Industry Trends
Growing prevalence of skin disorders increasing outsourcing demand for topical formulation manufacturing
The increasing occurrence of dermatological conditions such as eczema, psoriasis, acne, and other chronic skin disorders is expanding the need for effective topical therapies, supporting demand across the semi-solid dosage CDMO market. Pharmaceutical developers are increasingly relying on external manufacturing specialists to formulate and produce creams, ointments, gels, lotions, and other semi-solid products that require controlled processing and specialized expertise. Outsourcing allows drug developers to access formulation capabilities, manufacturing infrastructure, and quality systems without making extensive investments in dedicated production facilities. The need for scalable manufacturing of dermatology products is also increasing as treatment portfolios become more diversified and formulations require precise control over characteristics such as viscosity, consistency, drug distribution, and skin absorption.
Rising pharmaceutical R&D investments accelerating development of complex semi-solid drug formulations
Greater investment in pharmaceutical research and formulation development is creating opportunities for more sophisticated topical and semi-solid drug delivery systems. In the semi-solid dosage CDMO market, increasing R&D activity is encouraging pharmaceutical companies to develop formulations with improved stability, targeted delivery, enhanced bioavailability, and better patient usability. Complex formulations can require specialized equipment, analytical capabilities, process development expertise, and extensive formulation optimization, making CDMOs valuable partners during both development and commercialization stages. Demand is also supported by the growing need to translate laboratory-scale formulations into reproducible commercial manufacturing processes while maintaining product quality and regulatory compliance.
Strategic partnerships between pharma companies and CDMOs expanding specialized production capabilities
Pharmaceutical companies are increasingly forming strategic relationships with contract development and manufacturing organizations to access specialized formulation expertise and flexible production capacity. Such collaborations are strengthening the semi-solid dosage CDMO market by enabling drug developers to outsource selected stages ranging from formulation development and scale-up to commercial manufacturing and packaging. Long-term partnerships can also facilitate technology transfer, process optimization, and coordinated capacity planning for products with specialized manufacturing requirements. For CDMOs, deeper collaboration with pharmaceutical clients supports investment in dedicated technologies, formulation platforms, and production capabilities tailored to semi-solid drug products.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growing prevalence of skin disorders increasing outsourcing demand for topical formulation manufacturing | 1.90% | High | North America, Europe | High | Near Term |
| Rising pharmaceutical R&D investments accelerating development of complex semi-solid drug formulations | 1.70% | Moderate | North America, Asia Pacific | Medium | Mid Term |
| Strategic partnerships between pharma companies and CDMOs expanding specialized production capabilities | 1.50% | Moderate | Europe, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the semi-solid dosage CDMO market, North America held the largest share of 43.85% in 2026, supported by its established pharmaceutical manufacturing ecosystem, strong demand for outsourced drug development and production, and advanced capabilities in formulation and specialized dosage manufacturing. The region benefits from a mature regulatory environment and well-developed healthcare infrastructure, which encourage pharmaceutical companies to engage external manufacturing partners for complex semi-solid formulations. Continued emphasis on manufacturing efficiency, quality compliance, and flexible production capacity further reinforces North America's leading position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing regional market, driven by expanding pharmaceutical manufacturing capabilities, increasing healthcare demand, and the growing adoption of outsourcing models across the drug development and production value chain. Improvements in manufacturing infrastructure and regulatory capabilities are strengthening the region's attractiveness for pharmaceutical companies seeking scalable and cost-efficient production solutions. Rising investments in healthcare and pharmaceutical capacity, together with broader access to advanced formulation technologies, are expected to support sustained expansion of the semi-solid dosage CDMO market across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants/Startups i Scale Low Medium High | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Manufacturing Quality ExcellenceGermany emphasizes high-quality semi-solid dosage manufacturing supported by rigorous production standards and advanced pharmaceutical technologies. German CDMOs continue expanding specialized capabilities that enable efficient scale-up and reliable commercial manufacturing for topical products.
France 🇫🇷
Dermatology Manufacturing ExpertiseFrance maintains a strong focus on semi-solid dosage manufacturing for dermatology and topical therapeutic applications. French CDMOs emphasize formulation refinement, production consistency, and regulatory compliance to meet evolving pharmaceutical outsourcing requirements.
Italy 🇮🇹
Flexible Contract ManufacturingItaly strengthens its semi-solid dosage CDMO market through adaptable manufacturing services supporting pharmaceutical companies with varying production volumes. Italian providers prioritize efficient technology transfer, formulation support, and reliable commercial manufacturing for topical dosage forms.
Japan 🇯🇵
Specialized Topical ProductionJapan focuses on technically advanced manufacturing of creams, ointments, and gels requiring consistent formulation performance. Japanese CDMOs strengthen development and production capabilities that address specialized pharmaceutical quality and regulatory expectations for semi-solid dosage products.
South Korea 🇰🇷
Innovation Partnership GrowthSouth Korea expands semi-solid dosage CDMO capabilities through investments in modern manufacturing facilities and collaborative pharmaceutical development. Companies in South Korea increasingly support both domestic and international clients seeking flexible production and formulation expertise.
United States 🇺🇸
Formulation Development StrengthThe U.S. semi-solid dosage CDMO market benefits from strong demand for outsourced formulation development and commercial manufacturing services. CDMOs in the U.S. invest in flexible production capabilities that support topical pharmaceuticals, dermatology products, and complex formulation requirements.
Segment Leadership and Growth Trends
Semi-Solid Dosage CDMO Market Share (%), by Route of Administration, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportRoute of Administration Segment Analysis: Topical (Largest Segment) vs Transdermal (Fastest-Growing Segment)
The topical segment led the semi-solid dosage CDMO market in 2026, accounting for an 84.1% share. Its substantial position reflects the widespread use of creams, ointments, gels, and related formulations across pharmaceutical and healthcare applications. Topical delivery offers a direct application route and can be supported by established formulation processes, making outsourcing attractive to companies seeking specialized manufacturing expertise. Demand for flexible production capabilities, formulation development, and reliable commercial-scale manufacturing continues to strengthen the role of topical products within CDMO services.
Transdermal is expected to be the fastest-growing route of administration, supported by increasing interest in drug delivery approaches that can provide controlled and sustained absorption through the skin. Transdermal formulations can offer an alternative to conventional administration by improving convenience and supporting consistent delivery for appropriate therapies. Growing pharmaceutical interest in patient-friendly dosage forms, specialized formulation technologies, and differentiated delivery mechanisms is encouraging greater outsourcing demand for transdermal development and manufacturing.
End Use Segment Analysis: Pharmaceutical Companies (Largest Segment) vs Biopharmaceutical Companies (Fastest-Growing Segment)
Pharmaceutical companies accounted for the largest share of the semi-solid dosage CDMO market in 2026, representing 45.86%. Their leading position reflects continued outsourcing of formulation development and manufacturing activities to specialized CDMOs as pharmaceutical manufacturers seek greater operational flexibility and access to dedicated production capabilities. External partnerships can help pharmaceutical companies manage manufacturing complexity, expand formulation expertise, and streamline production while maintaining focus on core development and commercialization activities.
Biopharmaceutical companies are positioned as the fastest-growing end-use segment as their expanding therapeutic pipelines create greater demand for specialized development and manufacturing support. Increasing complexity in biopharmaceutical product development encourages reliance on external partners with formulation, process development, and manufacturing capabilities. The growing need for flexible capacity and specialized expertise is therefore supporting stronger engagement between biopharmaceutical companies and semi-solid dosage CDMOs.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Route of Administration | Topical, Transdermal, Others | Topical | Transdermal |
| End Use | Pharmaceutical Companies, Biopharmaceutical Companies, Others | Pharmaceutical Companies | Biopharmaceutical Companies |
| Product | Ointments, Creams and Lotions, Pastes, Gels, Others | Creams and Lotions | Ointments |
| Service | Contract Development, Contract Manufacturing | Contract Manufacturing | Contract Development |
Competitive Landscape and Market Positioning
Leading companies in the semi-solid dosage CDMO market:
1. Piramal Pharma Solutions (India)
2. Bora Pharmaceuticals Co. Ltd. (Taiwan)
3. Cambrex Corporation (United States)
4. Pierre Fabre Group (France)
5. Ascendia Pharmaceuticals Inc. (United States)
6. DPT Laboratories Ltd. (United States)
7. LGM Pharma LLC (United States)
8. Pace Analytical Life Sciences LLC (United States)
9. Catalent Inc. (United States)
The semi-solid dosage CDMO market is expanding through increasing demand for specialized topical and transdermal formulations. Contract manufacturers are investing in automated filling technologies, flexible production lines, and formulation optimization capabilities to improve manufacturing efficiency and scalability. Enhanced focus on customized pharmaceutical solutions and quality compliance standards is also driving market competitiveness.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Piramal Pharma Solutions (India) | |||||||
| Bora Pharmaceuticals Co. Ltd. (Taiwan) | |||||||
| Cambrex Corporation (United States) | |||||||
| Pierre Fabre Group (France) | |||||||
| Ascendia Pharmaceuticals Inc. (United States) | |||||||
| DPT Laboratories Ltd. (United States) | |||||||
| LGM Pharma LLC (United States) | |||||||
| Pace Analytical Life Sciences LLC (United States) | |||||||
| Catalent Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Blue Wolf Capital Partners | Sep-24 | Blue Wolf Capital Partners completed the acquisition of seven European manufacturing facilities from Recipharm. These sites, located in Sweden, France, and Spain, specialize in the development and production of oral solid, semi-solid, and liquid dosage forms. This acquisition forms the cornerstone of a new independent CDMO platform designed to provide expanded manufacturing services to global pharmaceutical clients. |
| MedPharm | Jul-24 | MedPharm and Tergus Pharma announced a strategic merger, operating under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. The combined entity leverages enhanced scientific capabilities, clinical trial manufacturing, and commercial-scale production, including specialized facilities for hormone-based and highly potent drug development. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Semi-Solid Dosage CDMO Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Therapeutic Area | Dermatology, Pain Management, Anti-Infectives, Hormonal Therapies, Other Therapeutic Areas |
| Molecule Type | Small-Molecule Drugs, Biologics & Peptides, Combination Products |
| Client Engagement Model | Early-Stage Development, Clinical-Stage Development & Manufacturing, Commercial Manufacturing |
Semi-Solid Dosage CDMO Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| CDMO Outsourcing Opportunity Assessment |
|
| Pharmaceutical Formulation Outsourcing Trends |
|
| Technology Adoption Roadmap for Semi-Solid Manufacturing |
|
Need a different cut of the data?
Request Custom ResearchHow big is the semi-solid dosage CDMO market?
What is the anticipated CAGR of the semi-solid dosage CDMO industry?
How is rising prevalence of skin disorders driving outsourcing demand in the semi-solid dosage CDMO market?
How are rising pharmaceutical R&D investments influencing semi-solid formulation complexity and CDMO demand?
Why does the Topical route dominate the semi-solid dosage CDMO market?
Why are biopharmaceutical companies the fastest-growing end-use segment in the semi-solid dosage CDMO market?
Why does North America lead the CDMO market?
How is Asia Pacific contributing to CDMO market growth?
Who are the major participants shaping the semi-solid dosage CDMO landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization